The CoronaVac vaccine, which contains inactivated SARS-CoV-2, the virus that causes COVID-19, led to a severe case of late-onset neuromyelitis optica spectrum disorder (NMOSD) in a 70-year-old woman. The unique case was described in an article, “Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A…
A man’s first manifestation of neuromyelitis optica spectrum disorder (NMOSD) was aseptic meningitis, an inflammation of the meninges (the membranes that enclose the brain and spinal cord) without evidence of a bacterial infection, which is unusual and made a quick diagnosis difficult, says a report from Japan. The man…
Vaccination against SARS-CoV-2, the virus that causes COVID-19, may trigger neuromyelitis optica spectrum disorder (NMOSD), a case report suggests. The report, “Antibody‐Positive Neuromyelitis Optica Spectrum Disorder After Second COVID‐19 Vaccination: a Case Report,” was published in the journal SN Comprehensive Clinical Medicine. Recommended…
Astrocytes, star-shaped cells found around nerve cells, make an inflammation driver of neuromyelitis optica spectrum disorder (NMOSD) called interleukin-6 (IL-6) in part by gearing up a chain of reactions involving nuclear factor kappa B, or NF-kappaB, according to a study in rat cells. Researchers also observed that by blocking…
Key players in B-cell signaling pathways and related inflammatory molecules were elevated in the blood of people with neuromyelitis optica spectrum disorder (NMOSD) compared with healthy people, a study found. The findings suggest that targeting this signaling pathway could show therapeutic promise in NMOSD, the researchers noted. The study,…
Self-reactive antibodies that cause most cases of neuromyelitis optica spectrum disorder (NMOSD) are released directly from immune B-cells in lymph nodes as opposed to cells in the bloodstream, a study has discovered. These findings implicate ongoing lymph node activity as the main driver of disease-causing antibody production in NMOSD.
Longer-term treatment with immunosuppressants may halve the risk of relapse, or of symptoms returning, in neuromyelitis optica spectrum disorder (NMOSD), a study in China found. When taken non-stop for up to five years, such treatment reduced the risk of relapse in NMOSD patients, with a mild rebound when immunosuppressants…
Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…
A specific pattern of brain inflammation called BPCLI sometimes can occur in people with neuromyelitis optica spectrum disorder (NMOSD), and often is associated with encephalitis-like symptoms that may contribute to misdiagnoses. A study with that finding, “Bilateral parafalcine cortical and leptomeningeal impairment: A characteristic pattern of MOG antibody…
Uplizna (inebilizumab-cdon) was found effective both at reducing attacks and lessening disability in people with neuromyelitis optica spectrum disorder (NMOSD) living in Europe, according to data from the N-MOmentum Phase 2/3 trial. Nearly 90% of participants given Uplizna remained free from attacks six months after starting the therapy,…
Get regular updates to your inbox.